Convalescent plasma treatment for SARS-CoV-2 infection: Analysis of the first 436 donors in England, 22 April to 12 May 2020

NHS Blood and Transplant Convalescent Plasma Testing Group

doi:10.2807/1560-7917.ES.2020.25.28.2001260

Convalescent plasma treatment for SARS-CoV-2 infection: Analysis of the first 436 donors in England, 22 April to 12 May 2020

NHS Blood and Transplant Convalescent Plasma Testing Group

Research output: Contribution to journal › Review article › peer-review

45 Citations (Scopus)

16 Downloads (Pure)

Abstract

Serological reactivity was analysed in plasma from 436 individuals with a history of disease compatible with COVID-19, including 256 who had been laboratory- confirmed with SARS-CoV-2 infection. Over 99% of laboratory-confirmed cases developed a measurable antibody response (254/256) and 88% harboured neutralising antibodies (226/256). Antibody levels declined over 3 months following diagnosis, emphasising the importance of the timing of convalescent plasma collections. Binding antibody measurements can inform selection of convalescent plasma donors with high neutralising antibody levels.

Original language	English
Journal	Eurosurveillance
Volume	25
Issue number	28
DOIs	https://doi.org/10.2807/1560-7917.ES.2020.25.28.2001260
Publication status	Published - 16 Jul 2020

Bibliographical note

Funding Information: This work was funded by the Department of Health and Social Care (DHSC)/UKRI/NIHR COVID-19 Rapid Response Grant (COV19-RECPLA).

Open Access: This is an open-access article distributed under the terms of the Creative Commons Attribution (CC BY 4.0) Licence. You may share and adapt the material, but must give appropriate credit to the source, provide a link to the licence and indicate if changes were made.

Publisher Copyright: This article is copyright of the authors or their affiliated institutions, 2020.

Citation: Harvala Heli , Mehew Jennifer , Robb Matthew L , Ijaz Samreen , Dicks Steven , Patel Monika , Watkins Nicholas , Simmonds Peter , Brooks Tim , Johnson Rachel , Gopal Robin , Roberts David J , Zambon Maria , the NHS Blood and Transplant Convalescent Plasma Testing Group . Convalescent plasma treatment for SARS CoV-2 infection: analysis of the first 436 donors in England, 22 April to 12 May 2020. Euro Surveill. 2020;25(28):pii=2001260.

DOI: https://doi.org/10.2807/1560-7917. ES.2020.25.28.2001260

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.2807/1560-7917.ES.2020.25.28.2001260Licence: CC BY

Harvala2020ConvalescentPlasmaTherapyForTheTreatmentTransfusMedFinal published version, 2.36 MBLicence: CC BY

Cite this

@article{30430ea507ad4612bdaa4689909cacf2,

title = "Convalescent plasma treatment for SARS-CoV-2 infection: Analysis of the first 436 donors in England, 22 April to 12 May 2020",

abstract = "Serological reactivity was analysed in plasma from 436 individuals with a history of disease compatible with COVID-19, including 256 who had been laboratory- confirmed with SARS-CoV-2 infection. Over 99% of laboratory-confirmed cases developed a measurable antibody response (254/256) and 88% harboured neutralising antibodies (226/256). Antibody levels declined over 3 months following diagnosis, emphasising the importance of the timing of convalescent plasma collections. Binding antibody measurements can inform selection of convalescent plasma donors with high neutralising antibody levels.",

author = "{NHS Blood and Transplant Convalescent Plasma Testing Group} and Heli Harvala and Jennifer Mehew and Robb, {Matthew L.} and Samreen Ijaz and Steven Dicks and Monika Patel and Nicholas Watkins and Peter Simmonds and Timothy Brooks and Rachel Johnson and Robin Gopal and Roberts, {David J.} and Maria Zambon",

note = "Funding Information: This work was funded by the Department of Health and Social Care (DHSC)/UKRI/NIHR COVID-19 Rapid Response Grant (COV19-RECPLA). Open Access: This is an open-access article distributed under the terms of the Creative Commons Attribution (CC BY 4.0) Licence. You may share and adapt the material, but must give appropriate credit to the source, provide a link to the licence and indicate if changes were made. Publisher Copyright: This article is copyright of the authors or their affiliated institutions, 2020. Citation: Harvala Heli , Mehew Jennifer , Robb Matthew L , Ijaz Samreen , Dicks Steven , Patel Monika , Watkins Nicholas , Simmonds Peter , Brooks Tim , Johnson Rachel , Gopal Robin , Roberts David J , Zambon Maria , the NHS Blood and Transplant Convalescent Plasma Testing Group . Convalescent plasma treatment for SARS CoV-2 infection: analysis of the first 436 donors in England, 22 April to 12 May 2020. Euro Surveill. 2020;25(28):pii=2001260. DOI: https://doi.org/10.2807/1560-7917. ES.2020.25.28.2001260",

year = "2020",

month = jul,

day = "16",

doi = "10.2807/1560-7917.ES.2020.25.28.2001260",

language = "English",

volume = "25",

journal = "Eurosurveillance",

issn = "1025-496X",

publisher = "European Centre for Disease Prevention and Control (ECDC)",

number = "28",

}

TY - JOUR

T1 - Convalescent plasma treatment for SARS-CoV-2 infection

T2 - Analysis of the first 436 donors in England, 22 April to 12 May 2020

AU - NHS Blood and Transplant Convalescent Plasma Testing Group

AU - Harvala, Heli

AU - Mehew, Jennifer

AU - Robb, Matthew L.

AU - Ijaz, Samreen

AU - Dicks, Steven

AU - Patel, Monika

AU - Watkins, Nicholas

AU - Simmonds, Peter

AU - Brooks, Timothy

AU - Johnson, Rachel

AU - Gopal, Robin

AU - Roberts, David J.

AU - Zambon, Maria

N1 - Funding Information: This work was funded by the Department of Health and Social Care (DHSC)/UKRI/NIHR COVID-19 Rapid Response Grant (COV19-RECPLA). Open Access: This is an open-access article distributed under the terms of the Creative Commons Attribution (CC BY 4.0) Licence. You may share and adapt the material, but must give appropriate credit to the source, provide a link to the licence and indicate if changes were made. Publisher Copyright: This article is copyright of the authors or their affiliated institutions, 2020. Citation: Harvala Heli , Mehew Jennifer , Robb Matthew L , Ijaz Samreen , Dicks Steven , Patel Monika , Watkins Nicholas , Simmonds Peter , Brooks Tim , Johnson Rachel , Gopal Robin , Roberts David J , Zambon Maria , the NHS Blood and Transplant Convalescent Plasma Testing Group . Convalescent plasma treatment for SARS CoV-2 infection: analysis of the first 436 donors in England, 22 April to 12 May 2020. Euro Surveill. 2020;25(28):pii=2001260. DOI: https://doi.org/10.2807/1560-7917. ES.2020.25.28.2001260

PY - 2020/7/16

Y1 - 2020/7/16

N2 - Serological reactivity was analysed in plasma from 436 individuals with a history of disease compatible with COVID-19, including 256 who had been laboratory- confirmed with SARS-CoV-2 infection. Over 99% of laboratory-confirmed cases developed a measurable antibody response (254/256) and 88% harboured neutralising antibodies (226/256). Antibody levels declined over 3 months following diagnosis, emphasising the importance of the timing of convalescent plasma collections. Binding antibody measurements can inform selection of convalescent plasma donors with high neutralising antibody levels.

AB - Serological reactivity was analysed in plasma from 436 individuals with a history of disease compatible with COVID-19, including 256 who had been laboratory- confirmed with SARS-CoV-2 infection. Over 99% of laboratory-confirmed cases developed a measurable antibody response (254/256) and 88% harboured neutralising antibodies (226/256). Antibody levels declined over 3 months following diagnosis, emphasising the importance of the timing of convalescent plasma collections. Binding antibody measurements can inform selection of convalescent plasma donors with high neutralising antibody levels.

UR - http://www.scopus.com/inward/record.url?scp=85088540621&partnerID=8YFLogxK

U2 - 10.2807/1560-7917.ES.2020.25.28.2001260

DO - 10.2807/1560-7917.ES.2020.25.28.2001260

M3 - Review article

C2 - 32700670

AN - SCOPUS:85088540621

SN - 1025-496X

VL - 25

JO - Eurosurveillance

JF - Eurosurveillance

IS - 28

ER -

Convalescent plasma treatment for SARS-CoV-2 infection: Analysis of the first 436 donors in England, 22 April to 12 May 2020

Abstract

Bibliographical note

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this